MAGE-A9 is frequently expressed in a variety of cancers27, 28, 29, 30, 31, 32, 33, 34, 35, which can provide additional prognostic information in renal cell carcinoma, bladder cancer, hepatocellular carcinoma, laryngeal squamous cell carcinoma, cutaneous T cell lymphomas and breast cancer. Here, MAGEA9 is linked to hereditary clear cell renal cell carcinoma.